The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
Diagnosis and Treatment of Neurocysticercosis: 2017 Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH)
Open accessAbstract
Guidelines for the clinical management of patients with neurocysticercosis (NCC) were prepared by a panel of the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH). The guidelines are intended for infectious disease specialists, neurologists, neurological surgeons, internists, pediatricians, and family practitioners. These guidelines present our approaches to the diagnosis and management of patients with the different forms of neurocysticercosis, including viable parenchymal neurocysticercosis, single enhancing lesions, calcified parenchymal neurocysticercosis, ventricular neurocysticercosis, and subarachnoid neurocysticercosis. Our recommendations are based on the best evidence available. Due to the complex variations in clinical manifestations and the limitations of the literature, many of the recommendations are based on observational studies, anecdotal data, or expert opinion rather than randomized clinical trials. The approaches we describe are intended to be both applicable and feasible in the United States and Canada (for simplicity, referred to here as North America). The recommendations may not apply for settings where resource constraints may limit their applicability. The executive summary below lists the recommendations for the diagnosis and clinical management of neurocysticercosis. A detailed description of the methods, background, and evidence summaries that support each of the recommendations can be found online in the full text of the guidelines. A criterion for grading evidence is presented in Figure 1 [1]. Note that diagnosis and management of patients with neurocysticercosis can be challenging even with expert guidelines. Due to this complexity, clinicians with little experience with this disease should have a low threshold for consultation with an expert in the disease. Grading of Recommendations, Assessment, Development and Evaluation (GRADE) framework for grading of evidence. While there is a wide range of clinical manifestations of neurocysticercosis, the 2 most common clinical presentations are with seizures and increased intracranial pressure (not graded). Initial evaluation should include careful history and physical examination, and neuroimaging studies (not graded). We recommend serologic testing with enzyme-linked immunotransfer blot as a confirmatory test in patients with suspected neurocysticercosis (strong, moderate). Enzyme-linked immunosorbent assays using crude antigen should be avoided due to poor sensitivity and specificity (strong, moderate). 4. We recommend both brain magnetic resonance imaging (MRI) and a noncontrast computed tomography (CT) scan for classifying patients with newly diagnosed neurocysticercosis (strong, moderate). The classification is outlined in Table 1. 5. We suggest screening for latent tuberculosis infection in patients likely to require prolonged corticosteroids (weak, low). 6. We suggest screening or empiric therapy for Strongyloides stercoralis in patients likely to require prolonged corticosteroids (weak, low). 7. We recommend that all patients with NCC undergo a funduscopic examination prior to initiation of anthelminthic therapy (strong, moderate). 8. We suggest that patients with NCC who probably acquired NCC in a nonendemic area have their household members screened for tapeworm carriage (weak, low). Remark: This is a public health issue and can often be addressed by the local health department. 9. We recommend that patients treated with albendazole for >14 days be monitored for hepatotoxicity and leukopenia (strong, moderate). 10. No additional monitoring is needed for patients receiving combination therapy with albendazole and praziquantel beyond that recommended for albendazole monotherapy (strong, moderate). 11. In patients with untreated hydrocephalus or diffuse cerebral edema, we recommend management of elevated intracranial pressure alone and not antiparasitic treatment (strong, moderate). Remarks: The management of patients with diffuse cerebral should be therapy as hydrocephalus a In the of elevated intracranial we recommend of antiparasitic in all patients with (strong, patients with viable parenchymal we recommend albendazole monotherapy for days to antiparasitic therapy (strong, or combination antiparasitic therapy (weak, moderate). Remarks: The of albendazole is 2 for days with We recommend a of We recommend albendazole with praziquantel for days rather than albendazole monotherapy for patients with viable parenchymal (strong, moderate). We suggest with antiparasitic therapy for parenchymal for the of the of therapy (weak, low). We recommend therapy prior to antiparasitic rather than therapy in all patients treated with antiparasitic therapy (strong, moderate). We recommend in all NCC patients with seizures (strong, low). In patients with seizures prior to antiparasitic of the on imaging studies, and seizures for we suggest that and be (weak, moderate). In the of da
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
GRADE: an emerging consensus on rating quality of evidence and strength of recommendations
Guyatt, G. H., Oxman, A. D., Vist, G. E., Kunz, R., Falck-Ytter, Y., Alonso-Coello, P., & Schünemann, H. J. (2008) · BMJ · doi:10.1136/bmj.39489.470347.ad · Cited by 23,305
GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology
Guyatt, G. H., Oxman, A. D., Schünemann, H. J., Tugwell, P., & Knottnerus, A. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.09.011 · Cited by 3,094
Tsang, V. C. W., Brand, J. A., & Boyer, A. E. (1989) · The Journal of Infectious Diseases · doi:10.1093/infdis/159.1.50 · Cited by 836
Lewinsohn, D. M., Leonard, M. K., LoBue, P. A., Cohn, D. L., Daley, C. L., Desmond, E., Keane, J., Lewinsohn, D. A., Loeffler, A. M., Mazurek, G. H., et al. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/ciw778 · Cited by 773
Clinical symptoms, diagnosis, and treatment of neurocysticercosis
Garcia, H. H., Nash, T. E., & Del Brutto, O. H. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70094-8 · Cited by 594
Self-citationNeurocysticercosis: A New Classification Based on Active and Inactive Forms
Sotelo, J., Guerrero, V., & Rubio, F. (1985) · Archives of Internal Medicine · doi:10.1001/archinte.145.3.442 · Cited by 511
(2000) · PubMed · Cited by 486
A Systematic Review of the Frequency of Neurocyticercosis with a Focus on People with Epilepsy
Ndimubanzi, P. C., Carabin, H., Budke, C. M., Nguyen, H., Qian, Y.-J., Rainwater, E., Dickey, M., Reynolds, S., & Stoner, J. A. (2010) · PLoS Neglected Tropical Diseases · doi:10.1371/journal.pntd.0000870 · Cited by 478
A Trial of Antiparasitic Treatment to Reduce the Rate of Seizures Due to Cerebral Cysticercosis
Garcia, H. H., Pretell, E. J., Gilman, R. H., Martinez, S. M., Moulton, L. H., Del Brutto, O. H., Herrera, G., Evans, C. A. W., & Gonzalez, A. E. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa031294 · Cited by 418
Self-citationDiagnosis and treatment of neurocysticercosis
Nash, T. E., & Garcia, H. H. (2011) · Nature Reviews Neurology · doi:10.1038/nrneurol.2011.135 · Cited by 253
Self-citationMeta-Analysis: Cysticidal Drugs for Neurocysticercosis: Albendazole and Praziquantel
Del Brutto, O. H., Roos, K. L., Coffey, C. S., & García, H. H. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-145-1-200607040-00009 · Cited by 231
Nash, T. E., Pretell, E. J., Lescano, A. G., Bustos, J. A., Gilman, R. H., Gonzalez, A. E., & Garcia, H. H. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70243-6 · Cited by 212
Self-citationGarcia, H. H., Gonzales, I., Lescano, A. G., Bustos, J. A., Zimic, M., Escalante, D., Saavedra, H., Gavidia, M., Rodriguez, L., Najar, E., et al. (2014) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(14)70779-0 · Cited by 190
Self-citationSubarachnoid basal neurocysticercosis: a focus on the most severe form of the disease
Fleury, A., Carrillo-Mezo, R., Flisser, A., Sciutto, E., & Corona, T. (2011) · Expert Review of Anti-infective Therapy · doi:10.1586/eri.10.150 · Cited by 173
Neurocysticercosis: Neglected but Not Forgotten
Coyle, C. M., Mahanty, S., Zunt, J. R., Wallin, M. T., Cantey, P. T., White, A. C., O'Neal, S. E., Serpa, J. A., Southern, P. M., Wilkins, P., et al. (2012) · PLoS Neglected Tropical Diseases · doi:10.1371/journal.pntd.0001500 · Cited by 172
Self-citationIs the Course of Neurocysticercosis Modified by Treatment With Antihelminthic Agents?
Carpio, A., Santillán, F., León, P., Flores, C., & Hauser, W. A. (1995) · Archives of Internal Medicine · doi:10.1001/archinte.1995.00430180088010 · Cited by 169
Self-citationForlenza, O. V., Filho, A. H. G. V., Nóbrega, J. P. S., Machado, L. D. R., de Barros, N. G., de Camargo, C. H. P., & da Silva, M. F. (1997) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.62.6.612 · Cited by 166
Prognosis for seizure recurrence in patients with newly diagnosed neurocysticercosis
Carpio, A., & Hauser, W. A. (2002) · Neurology · doi:10.1212/01.wnl.0000036320.69823.ea · Cited by 161
Self-citationNeurocysticercosis in Radiographically Imaged Seizure Patients in U.S. Emergency Departments1
Ong, S., Talan, D. A., Moran, G. J., Mower, W. R., Newdow, M., Tsang, V. C. W., Pinner, R. W., & the EMERGEncy ID NET Study Group (2002) · Emerging infectious diseases · doi:10.3201/eid0806.010377 · Cited by 149
Cysticercosis and cerebrovascular disease: a review.
Brutto, Ó. H. D. (1992) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.55.4.252 · Cited by 132
Evidence-based guideline: Treatment of parenchymal neurocysticercosis [RETIRED]
Baird, R. A., Wiebe, S., Zunt, J. R., HALPERIN, J. J., Gronseth, G., & Roos, K. L. (2013) · Neurology · doi:10.1212/wnl.0b013e31828c2f3e · Cited by 128
Neurocysticercosis: Focus on Intraventricular Disease
Cuetter, A. C., Garcia-Bobadilla, J., Guerra, L. G., Martinez, F. M., & Kaim, B. (1997) · Clinical Infectious Diseases · doi:10.1093/clinids/24.2.157 · Cited by 120
Hospitalization Frequency and Charges for Neurocysticercosis, United States, 2003–2012
O’Neal, S. E., & Flecker, R. H. (2015) · Emerging infectious diseases · doi:10.3201/eid2106.141324 · Cited by 116
Extraparenchymal Neurocysticercosis: Report of Five Cases and Review of Management
Bandrés, J. C., White, A. C., Samo, T., Murphy, E. C., & Harris, R. L. (1992) · Clinical Infectious Diseases · doi:10.1093/clind/15.5.799 · Cited by 114
Self-citationApplications of 3D CISS sequence for problem solving in neuroimaging
Hingwala, D., Chatterjee, S., Kesavadas, C., Thomas, B., & Kapilamoorthy, T. R. (2011) · Indian journal of radiology and imaging - new series/Indian journal of radiology and imaging/Indian Journal of Radiology & Imaging · doi:10.4103/0971-3026.82283 · Cited by 112
Frequency of Cerebral Arteritis in Subarachnoid Cysticercosis: An Angiographic Study
Barinagarrementería, F., & Cantú, C. (1998) · Stroke · doi:10.1161/01.str.29.1.123 · Cited by 106
Effect of administration of antihelminthics for soil-transmitted helminths during pregnancy
Salam, R. A., Haider, B. A., Humayun, Q., & Bhutta, Z. A. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005547.pub3 · Cited by 106
Albendazole trial at 15 or 30 mg/kg/day for subarachnoid and intraventricular cysticercosis
Góngora‐Rivera, F., Soto‐Hernández, J. L., González‐Esquivel, D. F., Cook, H. J., Márquez-Caraveo, C., Dávila, R. M., & Zambrano, J. S. (2006) · Neurology · doi:10.1212/01.wnl.0000195887.63124.dc · Cited by 105
Olveda, R. M., Acosta, L. P., Tallo, V. L., Baltazar, P. I., Lesiguez, J. L. S., Estanislao, G. G., Ayaso, E. B., Monterde, D. B. S., Ida, A., Watson, N. L., et al. (2015) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(15)00345-x · Cited by 103
Surgical management of neurocysticercosis
Rajshekhar, V. (2010) · International Journal of Surgery · doi:10.1016/j.ijsu.2009.12.006 · Cited by 94
Self-citationAlbendazole and praziquantel treatment in neurocysticercosis of the fourth ventricle
Proaño, J. V., Madrazo, I., García, L., García-Torres, E., & Correa, D. (1997) · Journal of neurosurgery · doi:10.3171/jns.1997.87.1.0029 · Cited by 90
Gogia, S., Talukdar, B., Choudhury, V., & Arora, B. S. (2003) · Transactions of the Royal Society of Tropical Medicine and Hygiene · doi:10.1016/s0035-9203(03)90075-7 · Cited by 87
High Prevalence of Asymptomatic Neurocysticercosis in an Endemic Rural Community in Peru
Moyano, L. M., O’Neal, S. E., Ayvar, V., Gonzálvez, G., Gamboa, R., Vilchez, P., Rodríguez, S., Reistetter, J., Tsang, V. C. W., Gilman, R. H., et al. (2016) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0005130 · Cited by 86
Self-citationCerebral Cysticercosis Treated Biphasically with Dexamethasone and Praziquantel
deGHETALDI, L. D., NORMAN, R. M., & DOUVILLE, A. W. (1983) · Annals of Internal Medicine · doi:10.7326/0003-4819-99-2-179 · Cited by 79
Garcia, H. H., Lescano, A. G., Gonzáles, I., Bustos, J. A., Pretell, E. J., Horton, J. D., Saavedra, H., Gonzalez, A. E., & Gilman, R. H. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw134 · Cited by 79
Self-citationAdded Value of Antigen ELISA in the Diagnosis of Neurocysticercosis in Resource Poor Settings
Gabriël, S., Blocher, J., Dorny, P., Abatih, E. N., Schmutzhard, E., Ombay, M., Mathias, B., & Winkler, A. S. (2012) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0001851 · Cited by 77
Endoscopic removal of cysticercal cysts within the fourth ventricle
Bergsneider, M. (1999) · Journal of neurosurgery · doi:10.3171/jns.1999.91.2.0340 · Cited by 75
Kaur, S., SINGHI, P. D., Singhi, S. C., & Khandelwal, N. K. (2009) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0b013e31819073aa · Cited by 73
Surgical treatment of cerebral cysticercosis: long-term results and prognostic factors
Colli, B. O., Carlotti, C. G., Assirati, J. A., Machado, H. R., Valênça, M. M., & Amato, M. C. M. (2002) · Neurosurgical FOCUS · doi:10.3171/foc.2002.12.6.4 · Cited by 70
Albendazole therapy for subarachnoid cysticerci: clinical and neuroimaging analysis of 17 patients.
Brutto, Ó. H. D. (1997) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.62.6.659 · Cited by 69
Suástegui, R., Soto‐Hernández, J. L., & Sotelo, J. (1996) · Journal of neurosurgery · doi:10.3171/jns.1996.84.4.0629 · Cited by 67
Cerebral cysticercosis and stroke.
Alarcón, F., Hidalgo, F., Moncayo, J., Viñán, I., & Dueñas, G. (1992) · Stroke · doi:10.1161/01.str.23.2.224 · Cited by 67
Drug therapy for solitary cysticercus granuloma
Otte, W. M., Singla, M., Sander, J. W. A. S., & Singh, G. (2012) · Neurology · doi:10.1212/wnl.0b013e31827b90a8 · Cited by 66
Self-citationFocal Limb Dystonia in a Patient With a Cerebellar Mass
Alarcón, F., TOLOSA, E. S., & Muñoz, E. (2001) · Archives of Neurology · doi:10.1001/archneur.58.7.1125 · Cited by 64
Neurocysticercosis in children
SINGHI, P. D., & Singhi, S. C. (2009) · The Indian Journal of Pediatrics · doi:10.1007/s12098-009-0139-5 · Cited by 59
Zhao, B.-C., Jiang, H., Ma, W., Jin, D., Li, H., Lü, H., Nakajima, H., Huang, T., Sun, K., Chen, S., et al. (2016) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0004418 · Cited by 59
Subarachnoidal Neurocysticercosis non-responsive to cysticidal drugs: a case series
Cárdenas, G., Carrillo‐Mezo, R., Jung, H., Sciutto, E., Soto‐Hernández, J. L., & Fleury, A. (2010) · BMC Neurology · doi:10.1186/1471-2377-10-16 · Cited by 58
Lanchote, V. L., Garcia, F. S., Dreossi, S. A. C., et al. (2002) · Therapeutic Drug Monitoring · doi:10.1097/00007691-200206000-00003 · Cited by 58
CYSTICERCOSIS OF THE EYE IN SOUTH INDIA – A CASE SERIES
Kaliaperumal, S., Rao, V., & Parija, S. (2005) · Indian Journal of Medical Microbiology · doi:10.1016/s0255-0857(21)02526-3 · Cited by 55
Circulating parasite antigen in patients with hydrocephalus secondary to neurocysticercosis.
Garcia, H. H., Gonzalez, A. E., Gilman, R. H., Bernal, T., Rodríguez, S., Pretell, E. J., Azcurra, O., Parkhouse, R. M. E., Tsang, V. C. W., Harrison, L. J. S., et al. (2002) · American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.2002.66.427 · Cited by 54
Self-citationAlbendazole : a comparison of relay embryotoxicity with embryotoxicity of individual metabolites.
Delatour, P., Parish, R. C., & Gyurik, R. J. (1981) · PubMed · Cited by 48
Chaurasia, R. N., Garg, R. K., Agarwal, A. K., Kohli, N., Verma, R. K., Singh, M. K., & Shukla, R. (2010) · PubMed · Cited by 44
Gupta, R. K., Awasthi, R., Garg, R. K., Kumar, N., Gupta, P. K., Singh, A. K., Sahoo, P., Paliwal, V. K., Prasad, K. N., Pandey, C. M., et al. (2012) · American Journal of Neuroradiology · doi:10.3174/ajnr.a3346 · Cited by 33
Bianchin, M. M., Velasco, T. R., Coimbra, É. R., Gárgaro, A. C., Escorsi-Rosset, S. R., Wichert‐Ana, L., Terra, V. C., Alexandre, V., Araújo, D., dos Santos, A. C., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0060949 · Cited by 31
Gupta, M., Agarwal, P., Khwaja, G. A., Chowdhury, D., Sharma, B., Bansal, J., & Anand, S. (2002) · PubMed · Cited by 30
Khade, P., Lemos, R. S., & Toussaint, L. G. (2011) · World Neurosurgery · doi:10.1016/j.wneu.2011.05.053 · Cited by 29
Sotelo, J., & Brutto, Ó. H. D. (1987) · Child s Nervous System · doi:10.1007/bf00274047 · Cited by 28
Concurrent asymptomatic inflammatory aneurysm and ischemic stroke due to cysticercal arteritis
Araúz, A., Ruiz-Navarro, F., Silos, H., Vargas‐González, J., Arguelles-Morales, N., Reyes, M., Ruíz-Franco, A., Rivera, A., & Fleury, A. (2013) · Clinical Neurology and Neurosurgery · doi:10.1016/j.clineuro.2013.10.001 · Cited by 14
Epilepsy surgery in context of neurocysticercosis
Singh, G., & Chowdhary, A. (2014) · Annals of Indian Academy of Neurology · doi:10.4103/0972-2327.128660 · Cited by 13
Self-citation
Metadata
- Authors
- White, A. C., Coyle, C. M., Rajshekhar, V., Singh, G., Hauser, W. A., Mohanty, A., Garcia, H. H., & Nash, T. E.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2018-02-22
- Volume
- 66
- Issue
- 8
- Pages
- e49-e75
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W4240368536
- Cited by
- 285
- References
- 59
- FWCI
- 8.72
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.